IRVINE, Calif.–(BUSINESS WIRE)–Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that it will present at the following two investor conferences in November:
Conference: Stephens NY Investment Conference
Location: New York, NY
Date: Tuesday, November 6, 2018
Presentation: 7:30 a.m. ET
Speakers: Vaseem Mahboob, Chief Financial Officer
Conference: Stifel Healthcare Conference
Location: New York, NY
Date: Wednesday, November 14, 2018
Presentation: 12:30 p.m. ET
Speakers: John Onopchenko, Chief Executive Officer, and Vaseem Mahboob, Chief Financial Officer
A live webcast of each presentation will be accessible through the “Investors” section of the Company’s website at www.endologix.com and will be available for replay following each event.
About Endologix, Inc.
Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company’s focus is endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 80%, making it a leading cause of death in the United States. For more information, visit www.endologix.com.
Contacts
INVESTORS:
Endologix, Inc.
Vaseem Mahboob, 949-595-7200
CFO
